Navigation Links
FDA Approves Rapid-Acting Insulin Apidra(R) for Treatment of Children with Diabetes
Date:10/29/2008

m regular human insulin by its rapid onset and shorter duration of action. When used as a mealtime insulin, Apidra(R) should be given within 15 minutes before or within 20 minutes after starting a meal. Due to the short duration of action of Apidra(R), patients also require a longer-acting insulin or insulin infusion pump therapy. Any change of insulin should be made cautiously and only under medical supervision. Tell your doctor about all other medicines and supplements you are taking. Glucose monitoring is recommended for all patients with diabetes.

Possible side effects may include low blood sugar; injection site reactions, such as changes in fat tissue at the injection site; and allergic reactions, such as itching and rash. Less common, but potentially more serious or life-threatening, is generalized allergy to insulin, including anaphylactic reactions.

When used in a pump, do not mix Apidra(R) with any other insulin or liquid. If the pump or infusion set does not work right, you may not receive the right amount of insulin. Hypoglycemia, hyperglycemia, or ketosis can happen. Problems should be identified and corrected as quickly as possible.

For full prescribing information, please visit http://www.Apidra.com.

IMPORTANT SAFETY INFORMATION FOR LANTUS(R)

Prescription Lantus(R) is for adults with type 2 diabetes or adults and children (6 years and older) with type 1 diabetes who require long-acting insulin for the control of high blood sugar.

DO NOT DILUTE OR MIX LANTUS(R) WITH ANY OTHER INSULIN OR SOLUTION. It will not work as intended, and you may lose blood sugar control, which could be serious. Do not change your insulin without talking with your doctor. The syringe must not contain any other medication or residue. You should not use Lantus(R) if you are allergic to insulin. Lantus(R) is a long-acting insulin you inject just once a day, at the same time each day. You mus
'/>"/>

SOURCE Sanofi-aventis
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
2. Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
3. FDA Approves Cymbalta(R) for Maintenance Treatment of Major Depressive Disorder
4. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
5. FDA Approves MiddleBrooks Amoxicillin PULSYS for Pharyngitis/Tonsillitis in Adolescents and Adults
6. FDA Approves XYZAL(R) (levocetirizine dihydrochloride) Oral Solution for the Relief of Seasonal and Year Round Allergies and Chronic Idiopathic Urticaria
7. UM Maryland Industrial Partnerships Program Approves 18 Collaborative Research Projects, Worth $4.4 Million, Between University Faculty, State Technology Companies
8. U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age)
9. U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older
10. FDA Approves HIFU Clinical Trial for Recurrent Prostate Cancer
11. EPA Approves XDS-CALUX(R) as Alternate Dioxin Test Method 4435
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... and ATLANTA , August 28, 2015 ... Food and Drug Administration (FDA) cleared the MagVita TMS Therapy ... patients who have failed to receive satisfactory improvement from prior ... technique for stimulating neural tissue in the part of the ... procedure has been proven safe and effective and MagVenture is ...
(Date:8/28/2015)... 28, 2015 , Joint research by ... from Biostar , Published in ,Stem Cells Translational ... lifespan through multiple IV administration of Adipose-derived MSC ... expectancy found , Commercialization within 5 years expected ... possibility that adult mesenchymal stem cells (MSCs) may extend ...
(Date:8/28/2015)... Massachusetts y LONDRES, 28 de agosto ... AEX: PHIA) anunció hoy su participación en el  ... exhibirá sus soluciones cardiológicas más recientes y novedosas, ... Cardiovascular, que conectan a las personas y la ... de ayudar a diagnosticar, guiar los tratamientos y ...
Breaking Medicine Technology:Therapy System for Treating Major Depressive Disorder Receives FDA Clearance 2Therapy System for Treating Major Depressive Disorder Receives FDA Clearance 3Korean Researchers Find the Possibility that Adult Mesenchymal Stem Cells (MSCs) May Extend Lifespan 2Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 2Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 3Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 4Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 5
... STEWARTVILLE, Minn., Sept. 12 Rochester,Medical Corporation ... publication of,results from a significant clinical study ... proprietary Infection Control Technology. The newly ... Internal Medicine",presents results of a randomized, double-blind, ...
... Include 1,000 mg Dose, PRINCETON, N.J., Sept. 12 ... discovery and development of novel,small molecule therapeutics, today announced ... multiple ascending dose (MAD) study of its lead,internal product ... with any of the doses under evaluation. As a ...
Cached Medicine Technology:Rochester Medical Anti-Infection Foley Catheter Demonstrates Effectiveness in Randomized Trial 2Rochester Medical Anti-Infection Foley Catheter Demonstrates Effectiveness in Randomized Trial 3Pharmacopeia Announces Positive Results from Phase 1 Multiple Ascending Dose Study of PS433540 (DARA) 2Pharmacopeia Announces Positive Results from Phase 1 Multiple Ascending Dose Study of PS433540 (DARA) 3Pharmacopeia Announces Positive Results from Phase 1 Multiple Ascending Dose Study of PS433540 (DARA) 4
(Date:8/29/2015)... ... August 29, 2015 , ... People who have ... (including emphysema), or asthma, are at higher risk from wildfire smoke especially in ... failure or heart-rhythm problems (arrhythmia or irregular heartbeat) are also sensitive to air ...
(Date:8/29/2015)... ... ... The popular television program VOICES IN AMERICA, hosted by legendary star of the stage ... short segment to the subject of diabetes. Diabetes is a debilitating health condition that ... recent advancements in medical science may prove to be a significant breakthrough that sufferers ...
(Date:8/28/2015)... ... , ... Rio Salado College joined nine educational institutions in Washington ... the EDUCAUSE - Next Generation Learning Challenges 2015 Breakthrough Models Incubator funded by the ... Models Incubator hosted by EDUCAUSE and NGLC, which is designed to bring leadership ...
(Date:8/28/2015)... Las Vegas, Nevada (PRWEB) , ... August 28, 2015 , ... ... is announcing its decision to make the purchase of CPAP equipment more affordable by ... This offer includes all types of CPAP products and orders of any size. My ...
(Date:8/28/2015)... ... August 28, 2015 , ... The Kentucky State Department of Workforce Investment ... position they are applying for, they are unable to pass the initial drug test ... drug testing policies in order to be able to hire long-term, skilled talent. (1) ...
Breaking Medicine News(10 mins):Health News:Heart Fit Clinic Sounds the Alarm on Forest Fire Smoke and Chronic Heart Disease in Calgary Area 2Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 2Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 3Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 4Health News:My Cpap Store Now Offering Delivery Special 0 Cost to You 2Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 2Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 3Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 4
... The percentage of physicians who provide free care to ... this is fast becoming huge problem for America’s quickly ... to a study conducted by the Center for Studying ... physicians provided charity care in the mid-1990s, compared with ...
... Institute of Technology has developed a new multi-functional sensing ... role in cystic fibrosis. // ,This ... tip of an atomic force microscope (AFM), creating a ... electrochemical activity at the cell surface. , ...
... Prolacta Bioscience, a for-profit company, started marketing a breast-milk concentrate ... their own milk on the Internet for $1 to $2.50 ... regulation and raise a lot of ethical and safety questions. ... at Presbyterian/St. Luke’s Medical Center said that this might affect ...
... well aware of Kawasaki as a motorcycle rather than a ... informed that his 9 year old daughter, Utkarsha was suffering ... as it is prevalent among Korean and Japanese children. 'I ... Kawasaki was a disease,' remarked Dinesh Ghai. ,Kawasaki ...
... found that babies born to women, who are hospitalized for ... APGAR scores and are more likely to be put under ... number of previous pregnancies, smoke more heavily and are less ... the April issue of Alcoholism: Clinical and Experimental Research. ...
... offer a pay of nearly $500,000 to the head of ... proposal, the Queensland Opposition has described it as being extravagant ... advertised for the post of a new director for the ... $500,000-plus. This is believed to pave way for enormous ...
Cached Medicine News:Health News:Fewer Doctors Treating For Free 2Health News:New Multi-functional Sensing Tool To Investigate Cystic Fibrosis 2Health News:New Multi-functional Sensing Tool To Investigate Cystic Fibrosis 3Health News:Mama’s milk on sal 2Health News:Low Awareness Of Kawasaki Disease In Capital: Parents Form Support Group 2Health News:Use Of Alcohol During Pregnancy Affects Newborns 2
... laryngoscope handles can be used with Portex® ... sturdy chrome blades with long-lasting bronze fiber-optic ... for continuous routine use., ,The laryngoscope ... of sizes, from infant to large adult, ...
... The FR-120F, Fujinon's new fiberoptic Naso-Pharyngo-Laryngoscope provides ... patient comfort. The latest in Fujinon ... increased light guide, and a wide 90 ... impressive 3.3mm distal tip diameter. In ...
... Articulating Tip Laryngoscopes are the ... Industry. The articulating tip aids ... an improved view of epiglottis. ... Optic styles. We guarantee your ...
CCR Medical fiberoptic green system laryngoscope handles., ,OUTSTANDING PERFORMANCE, QUALITY, AND PRICING MAKE OUR FIBEROPTIC SELECTION MOST ECONOMICAL....
Medicine Products: